Literature DB >> 10719851

Cystic schwannomas of the jugular foramen: clinical and surgical remarks.

G A Carvalho1, M Tatagiba, M Samii.   

Abstract

OBJECTIVE: The goals of this report were to outline the clinical presentation, radiological characteristics, surgical techniques, postoperative morbidity, and long-term follow-up results for cystic jugular foramen (JF) schwannomas and to describe their differences, compared with solid schwannomas involving the JF.
METHODS: A retrospective analysis of radiological studies and surgical records identified five primarily cystic tumors among 21 cases of JF schwannomas that had been surgically treated at our institution.
RESULTS: Two types of cystic JF schwannomas were observed, i.e., Type 1 lesions, which are single large cysts with thin ring-like enhancement of the tumor wall, and Type 2 lesions, which are multiple cysts with very irregular, thick enhancement of the cyst wall. The most common symptoms were hearing loss, ataxia, and headaches. Total surgical removal could be performed in all cases. The immediate postoperative findings indicated hearing improvement in three cases. No deterioration of lower cranial nerve function was observed. All patients were independent in the immediate postoperative period and in the long-term follow-up period (Karnofsky Performance Scale score, 90).
CONCLUSION: Surgical treatment of cystic JF schwannomas can be very demanding because of generally stronger adhesion of the tumor capsule to the surrounding structures, fragile tumor capsules, and difficulty in identification of the arachnoidal planes in some cases. Early identification of the arachnoidal planes without opening of the cyst and sharp dissection may be useful. Careful intradural opening of the JF should be performed to achieve total removal of the last tumor portion within the JF. A comparison of these lesions with solid schwannomas involving the JF indicated that cystic tumors affected a younger population, with less preoperative swallowing impairment (P < 0.05). The immediate postoperative course in both types of cystic JF schwannomas was usually better than for solid lesions, because of minor postoperative cranial nerve morbidity, especially involving lower cranial nerve function, in the latter cases. Long-term follow-up data failed to demonstrate any significant differences in final patient outcomes, however.

Entities:  

Mesh:

Year:  2000        PMID: 10719851     DOI: 10.1097/00006123-200003000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Long-term outcomes after surgical treatment of jugular foramen schwannoma.

Authors:  Masafumi Fukuda; Makoto Oishi; Akihiko Saito; Yukihiko Fujii
Journal:  Skull Base       Date:  2009-11

Review 2.  Differentiating imaging findings in primary and secondary tumors of the jugular foramen.

Authors:  Hubert Löwenheim; Andrei Koerbel; Florian H Ebner; Hidetaka Kumagami; Ulrike Ernemann; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2005-11-09       Impact factor: 3.042

3.  Facial and lower cranial nerve function preservation in lateral approach for craniocervical schwannomas.

Authors:  ZhaoYan Wang; HongSai Chen; Qi Huang; ZhiHua Zhang; Jun Yang; Hao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-14       Impact factor: 2.503

4.  Giant cystic sacral schwannoma mimicking tarlov cyst: a case report.

Authors:  Mark A Attiah; Peter P Syre; John Pierce; Elizaveta Belyaeva; William C Welch
Journal:  Eur Spine J       Date:  2015-07-21       Impact factor: 3.134

5.  The jugular foramen schwannomas: review of the large surgical series.

Authors:  Bulent Bakar
Journal:  J Korean Neurosurg Soc       Date:  2008-11-30

6.  The Bigger the Better? Analysis of Surgical Complications and Outcome of the Retrosigmoid Approach in 449 Oncological Cases.

Authors:  Amir Kaywan Aftahy; Ann-Kathrin Jörger; Sandra Hillebrand; Felix N Harder; Benedikt Wiestler; Denise Bernhardt; Stephanie E Combs; Bernhard Meyer; Chiara Negwer; Jens Gempt
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.